Mass General
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new approach to base editing.
Mass General Brigham Becomes Latest US Health System to Adopt Pretreatment DPYD Testing
The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense competition among Boston hospitals.
In OurHealth Study, Researchers Seek Genetic Underpinnings of Cardiovascular Disease in South Asians
Premium
Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ancestry are at increased risk.
Despite Overall Survival Miss, Singapore Researchers Champion Success of Global Cell Therapy Trial
Premium
The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell therapy to date.
'The Lead That Starts the Avalanche': Second Solid Tumor Cell Therapy Approval Energizes the Field
Premium
Adaptimmune's recent Tecelra approval further bolsters confidence in the feasibility of commercial approval for autologous cell therapies in solid tumors.